CCHT(000661)

Search documents
长春高新(000661) - 年度股东大会通知
2025-04-20 07:46
关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次:2024年度股东大会 证券代码:000661 证券简称:长春高新 公告编号:2025-027 长春高新技术产业(集团)股份有限公司 2、股东大会的召集人:公司第十一届董事会第九次会议决议提请召开股东大 会。 3、会议召开的合法、合规性:公司董事会认为本次股东大会会议的召开符合 有关法律、行政法规、部门规章、规范性文件、深交所业务规则和《公司章程》的 规定。 4、会议召开的日期、时间: (1)现场会议召开日期和时间:2025年5月12日14:00; (2)通过互联网投票系统的起止日期和时间:2025年5月12日9:15至当日 15:00期间的任意时间; (3)通过交易系统进行网络投票的起止日期和时间:2025年5月12日9:15- 9:25,9:30-11:30和13:00-15:00; 5、会议的召开方式:本次股东大会采用现场表决与网络投票相结合的方式召 开; 6、会议的股权登记日:2025 年 5 月 6 日; 7、出席对象: ( ...
长春高新(000661) - 监事会决议公告
2025-04-20 07:45
证券代码:000661 证券简称:长春高新 公告编号:2025-024 长春高新技术产业(集团)股份有限公司 第十一届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整,没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、长春高新技术产业(集团)股份有限公司(以下简称"公司")第十一届 监事会第七次会议于 2025 年 4 月 7 日以电话及微信方式发出会议通知。 2、会议于 2025 年 4 月 17 日 16 时以现场会议方式召开。 3、会议应出席监事 3 名,实际出席监事 3 名。 4、会议由监事会主席解兵主持。 5、本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定,会议合法有效。 二、监事会会议审议情况 本次会议审议通过了如下议案: 议案 1:《2024 年度监事会工作报告》 表决结果:3 票同意,0 票反对,0 票弃权。 内容详见公司同日披露于巨潮资讯网(www.cninfo.com.cn)的《2024 年度 监事会工作报告》。 本议案尚需提请公司 2024 年度股东大会审议。 议案 2:《2024 年年度报告全文及摘要 ...
长春高新(000661) - 董事会决议公告
2025-04-20 07:45
证券代码:000661 证券简称:长春高新 公告编号:2025-023 第十一届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、长春高新技术产业(集团)股份有限公司(以下简称"公司")第十一 届董事会第九次会议于 2025 年 4 月 7 日以电话及微信方式发出会议通知。 2、本次董事会于 2025 年 4 月 17 日 13 时 30 分以现场及通讯会议方式召开。 长春高新技术产业(集团)股份有限公司 1、《2024 年度董事会工作报告》 表决结果:9 票同意,0 票反对,0 票弃权。 3、本次会议应参与表决董事 9 名,实际参与表决董事 9 名。 4、会议由董事长姜云涛先生主持,公司监事、高级管理人员列席了本次会 议。 5、本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。 二、董事会会议审议情况 经与会董事认真讨论,审议并通过了如下议案: 内容详见公司同日披露于巨潮资讯网(www.cninfo.com.cn)的《2024 年度 董事会工作报告》。 本议案将提请公司 20 ...
长春高新(000661) - 2024年度利润分配方案公告
2025-04-20 07:45
证券代码:000661 证券简称:长春高新 公告编号:2025-030 长春高新技术产业(集团)股份有限公司 2024年度利润分配方案公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、 误导性陈述或重大遗漏。 长春高新技术产业(集团)股份有限公司(以下简称"公司")于 2025 年 4 月 17 日召开第十一届董事会第九次会议、第十一届监事会第七次会议,审议 通过了《2024 年度利润分配方案》,并同意将该议案提交公司 2024 年度股东大 会审议。现将相关事宜公告如下: 一、利润分配方案的基本情况 经大华会计师事务所(特殊普通合伙)审计,公司 2024 年度合并报表中归 属于上 市公司 股东 的净利 润为 2,583,058,408.54 元, 母公 司净利 润为 2,165,709,098.02 元,计提法定盈余公积金 216,570,909.80 元,任意盈余公积 金 216,570,909.80 元,加上期初未分配利润减去已实际分配的 2023 年度现金股 利 1,809,772,605.00 元,截至 2024 年 12 月 31 日,合并报表累计未分配利润为 17,48 ...
长春高新:一季度净利润同比下降44.95%
news flash· 2025-04-20 07:43
长春高新:一季度净利润同比下降44.95% 智通财经4月20日电,长春高新(000661.SZ)发布2025年第一季度报告,公司实现营业收入29.97亿元,同 比下降5.66%;归属于上市公司股东的净利润为4.73亿元,同比下降44.95%。主要原因是公司销售业务 相关人员数量增长导致费用增加,以及研发投入持续增长。 ...
长春高新(000661) - 2025 Q1 - 季度财报
2025-04-20 07:40
Financial Performance - The company's revenue for Q1 2025 was CNY 2,997,478,589.10, a decrease of 5.66% compared to CNY 3,177,355,203.27 in the same period last year[5] - Net profit attributable to shareholders was CNY 472,704,862.34, down 44.95% from CNY 858,728,236.98 year-on-year[5] - The basic earnings per share decreased to CNY 1.17, a decline of 45.07% compared to CNY 2.13 in the previous year[5] - Total operating revenue decreased to CNY 2,997,478,589.10 from CNY 3,177,355,203.27, representing a decline of approximately 5.65% year-over-year[19] - Total operating costs increased to CNY 2,422,413,505.22 from CNY 2,102,994,280.55, marking an increase of about 15.19% year-over-year[19] - Net profit attributable to the parent company decreased to CNY 472,704,862.34 from CNY 858,728,236.98, a decline of approximately 44.93% year-over-year[20] - Basic earnings per share decreased to CNY 1.17 from CNY 2.13, reflecting a drop of about 45% year-over-year[21] - Total comprehensive income decreased to CNY 468,710,472.39 from CNY 889,346,936.00, a decline of approximately 47.3% year-over-year[21] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 571,068,215.38, representing a 49.72% decrease from CNY 1,135,769,256.97 in the same period last year[5] - The net cash flow from investing activities was -2,697,676,383.92, indicating a significant outflow compared to the previous period's outflow of -659,395,909.82[24] - The net cash flow from financing activities was -75,189,681.00, a decrease from -480,108,431.16 in the prior period, reflecting reduced cash outflows[24] - The total cash and cash equivalents at the end of the period amounted to 3,828,444,255.44, down from 7,535,306,650.71 at the beginning of the period[24] - The cash and cash equivalents net increase for the period was -2,202,162,630.64, compared to -3,747,375.91 in the previous period[24] - Cash paid for debt repayment was 207,984,031.57, significantly lower than 629,301,008.75 in the prior period[24] - The company distributed dividends and interest payments totaling 17,251,796.63, compared to 9,345,037.33 previously[24] Assets and Liabilities - The total assets at the end of the reporting period were CNY 31,696,330,314.92, an increase of 2.08% from CNY 31,051,118,040.40 at the end of the previous year[5] - Total current assets decreased from CNY 16,270,250,650.56 to CNY 15,973,804,458.05, a decline of approximately 1.8%[15] - Total liabilities increased from CNY 4,948,673,308.81 to CNY 5,133,838,859.72, an increase of about 3.7%[17] - Total non-current assets increased from CNY 14,780,867,389.84 to CNY 15,722,525,856.87, an increase of approximately 6.4%[16] - Total equity attributable to shareholders increased to CNY 23,472,599,231.87 from CNY 22,999,514,866.29, an increase of approximately 2.05%[18] - Total liabilities and equity increased to CNY 31,696,330,314.92 from CNY 31,051,118,040.40, reflecting an increase of about 2.08%[18] Research and Development - The company continues to accelerate the R&D of key new products, including Class 1 innovative drugs, leading to increased R&D expenditures[10] - Research and development expenses increased to CNY 513,603,621.78 from CNY 421,532,747.26, an increase of about 21.8% year-over-year[20] Other Financial Metrics - The company reported a significant increase in sales personnel, contributing to higher expenses and impacting net profit[10] - Other comprehensive income after tax decreased to CNY -706,693.40 from CNY -2,362,751.60, indicating an improvement in losses[21] - The impact of exchange rate changes on cash and cash equivalents was -364,781.10, a minor change from -12,291.90 in the previous period[24] - The first quarter report was not audited, indicating that the financial data may be subject to further review[25] - The company will implement new accounting standards starting in 2025, which may affect future financial reporting[26]
长春高新(000661) - 2024 Q4 - 年度财报
2025-04-20 07:40
Financial Performance - The company's operating revenue for 2024 was CNY 13,465,627,318.38, a decrease of 7.55% compared to CNY 14,566,039,611.98 in 2023[19] - The net profit attributable to shareholders for 2024 was CNY 2,583,058,408.54, down 43.01% from CNY 4,532,483,532.14 in 2023[19] - The net profit after deducting non-recurring gains and losses was CNY 2,830,448,069.60, a decrease of 37.32% compared to CNY 4,515,660,901.70 in 2023[19] - The basic earnings per share for 2024 was CNY 6.42, a decline of 42.73% from CNY 11.21 in 2023[19] - The total cash dividends distributed for the year amounted to CNY 1,047,473,211.20, accounting for 56.81% of the annual net profit[5] - The company achieved a revenue of 13.466 billion yuan, a decrease of 7.55% compared to the same period last year[48] - The net profit attributable to shareholders was 2.583 billion yuan, down 43.01% year-on-year[48] - R&D investment reached 2.690 billion yuan, an increase of 11.20%, accounting for 19.97% of total revenue[49] - Sales expenses increased by 11.81% to 4.439 billion yuan, reflecting enhanced sales team recruitment and compliance efforts[50] Assets and Cash Flow - The total assets at the end of 2024 were CNY 31,051,118,040.40, representing a 1.00% increase from CNY 30,743,650,924.81 at the end of 2023[19] - The net assets attributable to shareholders increased by 4.19% to CNY 22,999,514,866.29 at the end of 2024, compared to CNY 22,074,934,790.14 at the end of 2023[19] - The cash flow from operating activities for 2024 was CNY 3,104,279,406.34, down 39.18% from CNY 5,103,687,813.05 in 2023[19] - The net cash flow from operating activities decreased by 39.18% to ¥3,104,279,406.34 in 2024 from ¥5,103,687,813.05 in 2023[109] Market and Industry Trends - The healthcare industry is increasingly important due to population aging and rising health awareness, with significant growth opportunities in the biopharmaceutical sector[28] - In 2024, the government aims to enhance the medical insurance system and promote the development of innovative drugs and medical devices[29] - The company is positioned to benefit from ongoing reforms in centralized drug procurement and medical insurance adjustments, enhancing market access and competitiveness[33] Product Development and Innovation - The company focuses on biopharmaceuticals and traditional Chinese medicine, with business segments covering gene engineering, biological vaccines, antibody drugs, high-end pharmaceuticals, and modern traditional Chinese medicine[35] - The gene engineering pharmaceutical segment, through its subsidiary JinSai Pharmaceutical, emphasizes children's and women's health, while also expanding into adult endocrine, dermatology, and oncology[36] - Key products include growth hormone series, follicle-stimulating hormone, and nutritional products, targeting various growth disorders in children[37] - The company is actively involved in the development of children's medications, responding to national policies aimed at improving pediatric healthcare services[34] - The company has introduced innovative products such as AI-based bone age assessment tools and growth development measurement devices[37] Regulatory Compliance and Governance - The company is focused on compliance and regulatory standards, responding to increased scrutiny in the pharmaceutical industry[32] - The company received an "A" rating in the annual information disclosure assessment by the Shenzhen Stock Exchange for 2024[142] - The company achieved a "AAA" rating in the ESG index assessment by the Shenzhen Stock Exchange[142] - The company has implemented a "Quality and Return Dual Improvement" action plan to enhance shareholder value and corporate governance[140] Environmental Compliance - The company has received various environmental permits, ensuring compliance with pollution discharge standards[194] - The company reported a chemical oxygen demand (COD) discharge of 15.38 mg/L, with a total of 0.4915 tons per year[1] - The company achieved a non-methane total hydrocarbon emission of 1.11 mg/Nm³, meeting the emission standards[2] - The company is focused on maintaining low emissions and adhering to environmental standards across all facilities[196] Strategic Partnerships and Acquisitions - The company acquired 100% of Changchun Yunxi Biopharmaceutical Co., Ltd. in 2024, expanding its operational scope[99] - The company has established strategic partnerships with multiple universities and hospitals to enhance research and clinical application, promoting innovation in medical technology[86] Employee and Management Structure - The company has a total of 11,547 employees, with 4,995 in sales, 3,808 in production, and 1,703 in technical roles[173] - The company has implemented a performance-linked floating salary system to enhance employee motivation and ensure high-quality development[174] - The company has a total of seven senior management personnel, ensuring effective daily operations and management[145] Future Outlook - The company provided an optimistic outlook for the next quarter, projecting a revenue increase of 25% to $625 million[155] - New product launches are expected to contribute an additional $50 million in revenue over the next fiscal year[156] - The company plans to expand its market presence and enhance product development in the upcoming fiscal year[152]
沪深300制药与生物科技指数报7370.94点,前十大权重包含片仔癀等
Jin Rong Jie· 2025-04-14 07:28
Group 1 - The Shanghai Composite Index opened high and the CSI 300 Pharmaceutical and Biotechnology Index reported 7370.94 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has decreased by 1.33% in the past month, increased by 5.20% in the past three months, and decreased by 0.98% year-to-date [1] - The CSI 300 Index is categorized into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten weights in the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (24.17%), WuXi AppTec (14.58%), Pian Zai Huang (6.92%), Yunnan Baiyao (5.68%), Kelun Pharmaceutical (5.11%), East China Pharmaceutical (3.63%), New Hope Liuhe (3.58%), Shanghai Raas (3.57%), Changchun High-tech (3.53%), and Fosun Pharma (3.39%) [1] - The market share of the CSI 300 Pharmaceutical and Biotechnology Index is 61.98% from the Shanghai Stock Exchange and 38.02% from the Shenzhen Stock Exchange [2] - The industry composition of the index includes: chemical drugs (42.08%), traditional Chinese medicine (20.00%), pharmaceutical and biotechnology services (19.84%), and biological drugs (18.08%) [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made when the CSI 300 Index samples are modified [2] - Special events affecting sample companies may lead to adjustments in the industry classification of the CSI 300 Industry Index [2]
4月2日早间重要公告一览
Xi Niu Cai Jing· 2025-04-02 04:54
Group 1: Company Performance - Western Gold achieved operating revenue of 7.001 billion yuan in 2024, a year-on-year increase of 56.68%, and net profit of 290 million yuan, turning from loss to profit [1] - Jihong Co. reported operating revenue of 5.529 billion yuan in 2024, a year-on-year decrease of 17.41%, with net profit down 47.28% to 182 million yuan [2] - Sanli Co. achieved operating revenue of 227 million yuan in 2024, a year-on-year increase of 14.35%, but reported a net loss of 49.88 million yuan, narrowing the loss by 56.50% [2] - Sanli Co. reported operating revenue of 2.590 billion yuan in 2024, a year-on-year increase of 25.25%, with net profit of 68.09 million yuan, up 59.07% [4] - Huaiqi Mountain achieved operating revenue of 1.631 billion yuan in 2024, a year-on-year increase of 15.60%, with net profit of 196 million yuan, up 17.74% [6] - Huayuan Holdings reported operating revenue of 2.449 billion yuan in 2024, a year-on-year increase of 1.60%, with net profit of 70.74 million yuan, up 739% [8] - Hangfa Power achieved operating revenue of 47.880 billion yuan in 2024, a year-on-year increase of 9.48%, but net profit decreased by 39.48% to 860 million yuan [10] - Zhongcai Energy reported operating revenue of 2.324 billion yuan in 2024, a year-on-year decrease of 24.21%, with net profit down 94.70% to 760,240 yuan [10] - Longxing Technology achieved operating revenue of 4.355 billion yuan in 2024, a year-on-year increase of 1.95%, with net profit of 142 million yuan, up 28.70% [11] - Jinying Co. reported operating revenue of 1.308 billion yuan in 2024, a year-on-year decrease of 4.52%, with net profit down 36.73% to 22.35 million yuan [12] - Zhujiang Co. achieved operating revenue of 1.558 billion yuan in 2024, a year-on-year decrease of 52.38%, but net profit turned to profit at 15.57 million yuan [12] - Chuanwang Media reported operating revenue of 288 million yuan in 2024, a year-on-year increase of 20.05%, but net profit decreased by 24.02% to 23.80 million yuan [13] - Ronglian Technology achieved operating revenue of 2.022 billion yuan in 2024, a year-on-year decrease of 14.91%, with net profit of 28.11 million yuan, up 107.87% [13] - Oufeiguang reported operating revenue of 20.437 billion yuan in 2024, a year-on-year increase of 21.19%, but net profit decreased by 24.09% to 58.38 million yuan [14] Group 2: Dividend Proposals - Western Gold proposed a cash dividend of 0.5 yuan per 10 shares [1] - Jihong Co. proposed a cash dividend of 1.58 yuan per 10 shares [2] - Sanli Co. proposed a cash dividend of 1.50 yuan per 10 shares [4] - Huaiqi Mountain proposed a cash dividend of 4.00 yuan per 10 shares [6] - Huayuan Holdings proposed a cash dividend of 1.00 yuan per 10 shares [8] - Hangfa Power proposed a cash dividend of 0.97 yuan per 10 shares [10] - Zhongcai Energy proposed a cash dividend of 0.05 yuan per 10 shares [10] - Longxing Technology proposed a cash dividend of 1.20 yuan per 10 shares [11] - Jinying Co. proposed a cash dividend of 1.00 yuan per 10 shares [12] - Zhujiang Co. proposed a cash dividend of 1.25 yuan per 10 shares [12] - Chuanwang Media proposed a cash dividend of 1.25 yuan per 10 shares [13] - Ronglian Technology proposed a cash dividend of 0.0425 yuan per share [13] - Oufeiguang proposed a cash dividend of 0.0178 yuan per share [14]
长春高新(000661) - 关于回购股份进展情况的公告
2025-04-01 11:20
证券代码:000661 证券简称:长春高新 公告编号:2025-021 长春高新技术产业(集团)股份有限公司 关于回购股份进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有 虚假记载、误导性陈述或重大遗漏。 长春高新技术产业(集团)股份有限公司(以下简称"公司")于2024年 11月14日召开了第十一届董事会第六次会议,审议通过了《关于公司回购股份 方案的议案》,同意公司使用自有资金及金融机构股票回购专项贷款资金以集 中竞价交易方式回购部分公司已在境内发行的人民币普通股(A股)股票,全 部用于后续实施公司及子公司核心团队股权激励或员工持股计划。拟用于回购 资金总额不低于人民币3亿元(含)、不超过人民币5亿元(含),回购价格不 超过人民币160.00元/股。具体回购股份数量以回购期限届满时实际回购的股份 数量为准。 上述内容详见公司于2024年11月16日、2024年11月21日在《中国证券报》 《证券时报 》 《 上 海 证 券 报 》 《 经 济 参 考 报 》 及 巨 潮 资 讯 网 ( http://www.cninfo.com.cn)上分别披露的《关于公司回购股份方案暨取得 ...